Laparoscopic Power Morcellators Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Laparoscopic Power Morcellators Market Trends and Insights

Adoption of Minimally Invasive Gynecological Surgery

The move from open surgery to laparoscopic treatment supports procedure volumes that use tissue extraction devices. A 2026 retrospective study found that laparoscopic myomectomy involved a 2.06-day hospital stay, compared with 2.71 days for laparotomy, and lower opioid use^{[1]S. Özdemir et al., “Laparotomic vs. Laparoscopic Myomectomy: Surgical Outcomes From a Tertiary Center Retrospective Study,” Frontiers in Surgery, frontiersin.org.}. These outcomes matter to hospitals because shorter stays can improve bed availability and reduce postoperative resource use. The laparoscopic power morcellators market gains a direct equipment demand link when laparoscopic myomectomy becomes the preferred pathway for eligible patients. Professional guidance issued by the European Society for Gynecological Endoscopy in 2024 supports laparoscopic abdominal myomectomy for fibroids up to 20 cm when surgeons have suitable experience. The laparoscopic power morcellators market, therefore, depends on training, operating room capacity, and surgeon confidence as much as on the number of women diagnosed with fibroids.

Persistent Burden of Uterine Fibroids and Endometriosis

Fibroids continue to create a large pool of patients who may need hysterectomy or myomectomy when symptoms cannot be managed conservatively. A 2026 study reported a global uterine-fibroid incidence rate of 250.93 per 100,000 women and an Indian rate of 326.08 per 100,000 women. The same work indicated that population growth would continue to support India’s fibroid case count through 2036. This disease burden supports the laparoscopic power morcellators market, where hospitals can provide trained minimally invasive gynecological care. It also makes the Asia-Pacific important because large case volumes can support equipment adoption once containment-compatible systems and training become available. Endometriosis remains relevant to the clinical setting, although fibroid treatment provides a more direct procedural base for tissue morcellation.

Demand for Fertility-Preserving Myomectomy

Myomectomy allows women with symptomatic fibroids to retain their uterus, making it important when fertility preservation is a clinical priority. The 2026 fibroid burden study found that global incidence was highest among women aged 35-39. Laparoscopic procedures require a way to remove fibroid tissue without extending the abdominal incision, which gives morcellation a specific role in this pathway. The laparoscopic power morcellators market benefits when surgeons can offer minimally invasive removal to patients who prefer uterus-preserving treatment. In countries with later childbearing, surgeons may see patients with larger or multiple fibroids during the years when fertility remains important. This can increase tissue extraction needs per procedure rather than only increasing the number of procedures.

Expansion of Ambulatory Surgical Centers

Ambulatory surgical centers are becoming a more important setting for procedures that previously took place mainly in hospitals. CMS added 37 procedures to the ASC covered-procedure list in 2024 and 21 procedures in 2025^{[2]Centers for Medicare & Medicaid Services, “Ambulatory Surgical Center Payment,” CMS.gov, cms.gov.}. These changes widen the range of outpatient procedures that can receive Medicare payment. A Maryland center became the first ASC in its region to offer robotic-assisted minimally invasive gynecological surgery in January 2026, showing that providers are moving more complex care into outpatient facilities. The laparoscopic power morcellators market can gain from this shift, but ASC buyers often favor systems with short setup times and clear disposable-use economics. Group purchasing arrangements and constrained capital budgets can also make these sites less receptive to expensive reusable platforms.

Risk of Disseminating Occult Malignancy

The possibility of spreading unsuspected uterine cancer during morcellation remains the most serious clinical barrier in the laparoscopic power morcellators market. The FDA states that unsuspected uterine sarcoma may be present in 1 in 225 to 1 in 580 women undergoing surgery for presumed fibroids^{[3]U.S. Food and Drug Administration, “Power Morcellation During Gynecologic Laparoscopic Surgeries,” FDA.gov, fda.gov.}. The agency also warns that power morcellation can spread cancerous tissue and reduce the likelihood of long-term survival. No preoperative test can reliably rule out uterine sarcoma in every patient with presumed fibroids, so selection decisions retain a clinical uncertainty. That uncertainty encourages hospitals and payers to limit use to carefully selected premenopausal patients. The laparoscopic power morcellators market must therefore compete with alternative surgical approaches, even when minimally invasive treatment would otherwise be preferred.

Stringent Patient-Selection and Containment Requirements

FDA guidance limits the use of laparoscopic power morcellation to appropriately selected patients and directs providers to use a legally marketed compatible containment system when the procedure is appropriate. Manufacturers must define the compatible morcellators in containment-system labeling, which requires formal evidence and creates an additional commercialization step. A 2025 survey of minimally invasive gynecologic surgery fellows reported that more than 80% did not consistently follow FDA-cleared containment protocols, and nearly half used specimen-retrieval bags off-label. These findings point to workflow and training barriers, not only to clinical disagreement. France’s medicines agency reported in 2025 that the 14 operators reviewed in its 2023 market-surveillance exercise had met the relevant labeling, patient-information, and risk-analysis recommendations. The laparoscopic power morcellators market will favor suppliers that make compatibility evidence and operating protocols simple for clinical teams to use.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Application: Hysterectomy Anchors Revenue While Tissue Removal Leads Growth

Hysterectomy accounted for 58.7% of the laparoscopic power morcellators market share in 2025, making it the largest application. The United States performs an estimated 600,000 hysterectomies each year, and the supplied research identified enlarged uteri requiring specialized extraction techniques in 30% of these procedures. The scale of this procedural base helps preserve demand for compatible tissue extraction equipment. FDA recommendations have made containment a defining element of use when power morcellation is appropriate, rather than an optional add-on. 

Gynecological tissue removal is projected to grow at a 10.5% CAGR through 2031, the fastest rate among applications. The laparoscopic power morcellators market size for this application expands as tissue extraction is used in procedures outside the traditional hysterectomy and myomectomy classifications. Some of this growth reflects more specific coding of tissue-removal steps that were previously included within broader procedures. The Claria System received FDA De Novo authorization in July 2026 as an integrated gynecologic power morcellator and containment system for laparoscopic hysterectomy in selected premenopausal patients. Its authorization encourages developers to consider integrated configurations for other gynecological tissue-removal uses, while myomectomy remains supported by fertility-preservation demand.

By End User: Hospitals Retain Scale While ASCs Change Buying Priorities

Hospitals held 62.4% of the laparoscopic power morcellators market share in 2025. Their position reflects the concentration of complex gynecological surgery, inpatient monitoring capacity, and established training programs within hospital systems. Academic medical centers also influence purchasing because they manage difficult cases and contribute clinical evidence on containment practices. Hospitals need product demonstrations, compatibility assessments, and formal surgeon training before adopting a new workflow. These requirements favor suppliers with direct clinical-support capabilities in the laparoscopic power morcellators market.

Ambulatory surgical centers are forecast to grow at an 11.5% CAGR through 2031, the fastest end-user rate. The expansion of covered outpatient procedures supports this movement, as does provider investment in robotic and minimally invasive gynecological care. ASCs are likely to favor lighter systems, single-use components, and predictable costs because their procedures must fit same-day schedules. This preference can shift product demand away from high-cost reusable capital platforms. It can also reward integrated containment approaches that reduce device coordination and setup steps.

By Distribution Channel: Direct Sales Leads While Digital Procurement Expands

Direct sales accounted for 47.7% of distribution-channel revenue in 2025. Capital morcellator systems need in-person clinical demonstrations, compatibility testing, and surgeon education, which makes a dedicated manufacturer sales force useful. Medical-device distributors and hospital procurement groups remain important where manufacturers do not have a strong direct presence. Third-party resellers serve price-sensitive facilities and regions that have limited access to primary inventories. These channels keep the laparoscopic power morcellators market accessible beyond large hospital accounts.

Online medical equipment platforms are forecast to grow at a 10.4% CAGR through 2031. Their growth is concentrated in consumables, including containment bags, disposable blade cartridges, and retrieval sacs, rather than in capital consoles. Digital systems can help hospitals and ASCs manage repeat orders and document product availability. Suppliers with proprietary disposable components can build recurring revenue through these purchasing routes. The shift does not replace direct sales for complex equipment, but it adds a digital channel for ongoing clinical supply needs.

Geography Analysis

North America held 43.7% of the laparoscopic power morcellators market share in 2025. The region combines high gynecological procedure volumes with established laparoscopic infrastructure and regulatory requirements that influence global device design. FDA guidance requires compatible containment when laparoscopic power morcellation is appropriate, which makes product validation central to procurement. The FDA authorized the Claria System through the De Novo pathway in July 2026 and created the SIM product code for this device type. This gives hospitals a defined integrated-system option as they update legacy configurations. The growing ASC base also creates new outpatient demand, although these sites will assess device cost and workflow carefully. Canada and Mexico represent smaller opportunities shaped by public procurement and insurance arrangements.

Europe has stable demand from Germany, the United Kingdom, France, and Italy because these countries have trained specialist workforces and established hospital purchasing systems. The EU Medical Device Regulation increased post-market surveillance and evidence expectations for device suppliers. These requirements can limit smaller suppliers’ participation in tenders while rewarding firms with documented clinical and regulatory support. France’s ANSM stated in 2025 that all 14 audited operators had aligned their labeling, patient communication, and risk analysis with national recommendations. Europe consequently offers a setting where validated containment workflows may command stronger pricing than basic standalone devices.

Asia-Pacific is forecast to grow at a 9.5% CAGR through 2031, the highest regional rate. India’s fibroid incidence rate of 326.08 per 100,000 women creates a substantial potential pool of surgically eligible patients. China recorded nearly 986,000 uterine-fibroid incident cases in 2021 in the supplied research, and expanding hospital training capacity supports procedure growth. Japan remains a more mature setting for laparoscopic myomectomy, with its existing precautions emphasizing safe use. The laparoscopic power morcellators market in the region will depend on hospital investment, training, and access to compatible containment products. Middle East and Africa and South America remain smaller, with demand concentrated in GCC private healthcare systems and Brazil’s large hospital networks.